Paricalcitol

Welcome to Dwaey, specifically on Paricalcitol page.
This medicine contains important and useful components, as it consists of
Paricalcitol is available in the market in concentration.

Generic Name of Paricalcitol - Learn More

Paricalcitol

Paricalcitol Precaution - What You Need to Know

Before initiating treatment with paricalcitol, it is essential for patients to consult their healthcare provider to ensure the medication is appropriate for their condition. Key precautions include:

- Hypercalcemia: Paricalcitol is a synthetic vitamin D analogue that may increase calcium levels in the blood. Patients should have their serum calcium levels monitored regularly to avoid hypercalcemia, which can lead to complications such as kidney stones, bone pain, or abnormal heart rhythms.
- Renal Impairment: Paricalcitol is primarily used in patients with chronic kidney disease (CKD), but dose adjustments may be needed depending on the degree of renal impairment. Monitoring of renal function, including serum creatinine and glomerular filtration rate (GFR), is recommended.
- Hypersensitivity: Patients with a known hypersensitivity to paricalcitol or any components of the formulation should avoid this medication.
- Pregnancy and Breastfeeding: Paricalcitol should be used cautiously during pregnancy. It is classified as a category C drug, meaning risk to the fetus cannot be ruled out. It is also excreted in breast milk, so breastfeeding mothers should discuss potential risks with their healthcare provider.
- Hyperphosphatemia: Paricalcitol can exacerbate hyperphosphatemia (elevated phosphate levels), particularly in patients with CKD. Close monitoring of phosphate levels is essential during treatment.

Paricalcitol Indication - Uses and Benefits

Paricalcitol is primarily used to manage disorders associated with parathyroid hormone (PTH) and calcium metabolism, particularly in patients with chronic kidney disease (CKD). Its therapeutic indications include:

- Secondary Hyperparathyroidism in Chronic Kidney Disease: Paricalcitol is used to treat secondary hyperparathyroidism (elevated PTH levels) in patients with CKD stages 3 and 4 who are on dialysis. It helps regulate PTH levels, calcium, and phosphate balance.
- Prevention of Bone Disease: By controlling PTH levels, paricalcitol helps prevent bone disease, which is a common complication of CKD, including conditions like renal osteodystrophy.
- Hypocalcemia Prevention: In dialysis patients, paricalcitol can help prevent or treat low blood calcium levels, which can arise due to altered calcium metabolism in CKD.

Paricalcitol Contraindications - Important Warnings

There are specific conditions in which paricalcitol should not be used to ensure patient safety:

- Hypercalcemia: Paricalcitol is contraindicated in patients with pre-existing hypercalcemia (elevated calcium levels) as it can exacerbate the condition.
- Vitamin D Toxicity: Patients with vitamin D toxicity or elevated levels of 25-hydroxyvitamin D should avoid paricalcitol, as it can increase the risk of further toxicity.
- Severe Hyperphosphatemia: Paricalcitol should be avoided in patients with severe hyperphosphatemia, as it can worsen this condition and increase the risk of cardiovascular complications or bone disease.

Paricalcitol Side Effects - What to Expect

Paricalcitol may cause side effects, both mild and severe. Common and severe side effects include:

- Common Side Effects:
- Nausea and vomiting
- Headache
- Fatigue or weakness
- Diarrhea or constipation
- Abdominal pain
- Upper respiratory infections

- Serious Side Effects:
- Hypercalcemia: Excessive calcium levels, which can lead to symptoms such as confusion, fatigue, muscle weakness, nausea, vomiting, and heart arrhythmias. Severe hypercalcemia requires immediate medical attention.
- Hyperphosphatemia: Elevated phosphate levels can occur, leading to bone and cardiovascular complications. Monitoring of phosphate levels is essential.
- Kidney Dysfunction: Paricalcitol should be used with caution in patients with severe kidney impairment. Close monitoring of renal function is required, and dose adjustments may be needed in cases of renal deterioration.
- Allergic Reactions: Rarely, paricalcitol may cause allergic reactions, such as skin rashes, swelling, or difficulty breathing, which require immediate medical attention.

Patients should contact their healthcare provider if they experience signs of hypercalcemia, such as muscle weakness or irregular heartbeats, or any severe allergic reactions.

Paricalcitol Pregnancy Category ID - Safety Information

3

Paricalcitol Mode of Action - How It Works

Paricalcitol is a synthetic vitamin D analogue that works by binding to the vitamin D receptor and modulating calcium and phosphate metabolism. Its mechanism of action involves:

- Inhibition of Parathyroid Hormone Secretion: Paricalcitol decreases the secretion of parathyroid hormone (PTH), which is elevated in patients with CKD and secondary hyperparathyroidism. By reducing PTH levels, it helps regulate calcium and phosphate homeostasis.
- Regulation of Calcium and Phosphate: Paricalcitol indirectly helps increase calcium absorption from the gut and reduces phosphate retention, contributing to better bone health and preventing the development of renal osteodystrophy.
- Prevention of Bone Disease: By controlling PTH levels, paricalcitol prevents bone demineralization and promotes proper bone mineralization, thereby reducing the risk of fractures and bone pain in CKD patients.

Paricalcitol Drug Interactions - What to Avoid

Paricalcitol may interact with several drugs, altering its effectiveness or causing adverse effects:

- Calcium-Containing Supplements: Concurrent use of calcium-containing supplements with paricalcitol can increase the risk of hypercalcemia. Calcium levels should be closely monitored.
- Phosphate Binders: Phosphate binders (e.g., calcium carbonate, sevelamer) may alter phosphate and calcium balance. Adjustments to phosphate binder doses may be necessary.
- Magnesium-Containing Antacids: Use of magnesium-containing antacids with paricalcitol can increase the risk of hypermagnesemia. Careful monitoring is advised.
- Corticosteroids: Corticosteroids may reduce the effectiveness of paricalcitol in regulating calcium and PTH levels. Monitoring is necessary if both drugs are used.
- Loop Diuretics: Loop diuretics such as furosemide can increase calcium excretion, potentially reducing the efficacy of paricalcitol in maintaining calcium balance.

Paricalcitol Adult Dose - Recommended Dosage

The dosing of paricalcitol depends on the patient's serum parathyroid hormone (PTH) levels and their response to therapy. For most adults with CKD, the usual starting dose is:

- For Secondary Hyperparathyroidism: The initial dose is typically 1 mcg to 2 mcg three times per week. The dose may be adjusted based on the patient’s response, with a typical range of 2 mcg to 4 mcg three times per week.
- Maintenance Dose: After titration, the maintenance dose may range from 1 mcg to 4 mcg three times per week.

Paricalcitol is administered intravenously, typically during dialysis sessions, or as prescribed by a healthcare provider.

Paricalcitol Child Dose - Dosage for Children

The safety and efficacy of paricalcitol in pediatric patients have not been fully established. It is not typically recommended for use in children unless prescribed by a specialist. In exceptional cases, the dose will be carefully adjusted by healthcare providers based on the child’s age, weight, and condition.

---
As always, it is crucial for patients to consult their healthcare provider before starting paricalcitol to ensure that it is appropriate for their condition and to discuss any potential risks, side effects, or necessary dose adjustments based on their health status.

Paricalcitol Renal Dose - Dosage for Kidney Conditions

Paricalcitol is primarily used in patients with chronic kidney disease, particularly those on dialysis. Dose adjustments may be necessary depending on the stage of renal impairment:

- Dialysis Patients: No dose adjustment is typically needed in dialysis patients, but regular monitoring of PTH, calcium, and phosphate levels is recommended to ensure appropriate dosing.
- Non-Dialysis Patients: For non-dialysis patients with severe renal impairment, dose adjustments are recommended based on serum calcium and phosphate levels. Careful monitoring is essential.